Gly-Pro-Glu protects β-amyloid-induced somatostatin depletion in the rat cortex

NeuroReport

Volumn 15, Issue 12, 2004, Pages 1979-1982

  Aguado Llera, David ^a   Martín Martínez, Mercedes ^b   García López, María Teresa ^b   Arilla Ferreiro, Eduardo ^c   Barrios, Vicente ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Adenylyl cyclase; Alzheimer's disease; Amyloid peptide; GPE; Neuroprotection; Somatostatin; Temporal cortex

Indexed keywords

ADENYLATE CYCLASE; AMYLOID BETA PROTEIN; GLYCYLPROLYLGLUTAMIC ACID; PEPTIDE; PEPTIDE HORMONE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BRAIN PROTECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HORMONE ACTION; IN VIVO STUDY; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEPLETION; PROTEIN FUNCTION; RAT; TEMPORAL CORTEX;

ADENYLATE CYCLASE; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ANIMALS; BINDING SITES; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; OVARIECTOMY; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TEMPORAL LOBE; TIME FACTORS;

EID: 4444252545     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200408260-00029     Document Type: Article

References (25)

1. Mattson PM. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivates. Physiol Rev 1997; 77:1081-1132.
2. Torres-Alemán I, Barrios V and Berdano J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology 1998; 50:772-776.
3. Sara VR, Carlsson-Skwirut C, Bergman T, Jörnvall H, Roberts PJ, Crawford M et al. Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide. Biochem Biophys Res Commun 1989; 165:766-771.
4. Sizonenko SV, Sirimanne ES, Williams CE and Gluckman PD. Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the inmature rat brain after hypoxic-ischemic injury. Brain Res 2001; 922:42-50.
5. Saura J, Curatolo L, Williams CE, Gatti S, Benatti L, Peeters C et al. Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro. NeuroReport 1999; 10:161-164.
6. Sara VR, Carlsson-Skwirut C, Drakenberg K, Giacobini MB, Hakanson L, Mirmiran M et al. The biological role of truncated insulin-like growth factor-1 and the tripeptide GPE in the central nervous system. Ann NY Acad Sci 1993; 692:183-191.
7. Bissette G, Cook L, Smith W, Dole KC, Crain B and Nemeroff CB. Regional neuropeptide pathology in Alzheimer's disease: corticotropin-releasing factor and somatostatin. J Alzheimers Dis 1998; 1:91-105.
8. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000; 283:1007-1015.
9. Barrios V, Puebla L, Rodríguez-Sanchez MN and Arilla E. Brain somatostatinergic system at late pregnancy, parturition and the early postpartum period in the rat. Reg Pept 1993; 48:355-363.
10. Nag S and Tang F. The effect of age on the response of the rat brains to continuous beta-amyloid infusion. Brain Res 2001; 889:303-307.
11. Schonknecht P, Pantel J, Klinga K, Jensen M, Hartmann T, Salbach B and Schroder J. Reduced cerebrospinal fluid estradiol levels are associated with increased beta-amyloid levels in female patients with Alzheimer's disease. Neurosci Lett 2001; 307:122-124.
12. Goodman Y, Bruce AJ, Cheng B and Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem 1996; 66: 1836-1844.
13. Patel YC and Reichlin S. Somatostatin in hypothalamus, extrahypothalamic brain and peripheral tissues of the rat. Endocrinology 1978; 102:523-530.
14. Czernik AJ and Petrack V. Somatostatin receptor binding in rat cerebral cortex. Characterization using a nonreducible somatostatin analog. J Biol Chem 1983; 285:5525-5530.
15. Gilman AG. A protein binding assay for adenosine 3′5′-cyclic monophosphate. Proc Natl Acad Sci USA 1970; 67:305-312.
16. Beal MF, Mazurek MF, Tran VT, Chattha G, Bird ED and Martin JB. Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. Science 1985; 229:289-291.
17. Chan-Palay V. Somatostatin immunoreactive neurons in the hippocampus and cortex shown by immunogold/silver intensification on vibratome sections: coexistence with neuropeptide Y neurons, and effects in Alzheimer's disease. J Camp Neurol 1986; 260:201-223.
18. Tapia-Arancibia L and Astier H. Actions of excitatory amino acids on somatostatin release from cortical neurons in primary cultures. J Neurochem 1989; 53:1134-1141.
19. Figueredo-Cardenas G, Anderson KD, Chen Q, Veenman CL and Reiner A. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats. Exp Neurol 1994; 129; 37-56.
20. Ioudina M and Uemura E. A three amino add peptide, Gly-Pro-Arg, protects and rescues cell death induced by amyloid β-peptide. Exp Neurol 2003; 184:923-929.
21. Guan J, Waldvogel HJ, Faull RL, Gluckman PD and Williams CE. The effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate in different regions following hypoxic-ischemic brain injury in adult rats. Neuroscience 1999; 89:649-659.
22. Bourguignon JP, Gérard A, Alvarez-González ML and Franchimont P. Acute suppression of gonadotropin-releasing hormone secretion by insulin-like growth factor I and subproducts: an age-dependent endocrine effect. Neuroendocrinology 1993; 58:525-530.
23. Rodríguez-Sánchez MN, Puebla L, López-Sañudo S, Rodríguez-Martín E, Martín-Espinosa A, Rodríguez-Pena MS et al. Dopamine enhances somatostatin receptor-mediated inhibition of adenylate cyclase in rat striatum and hippocampus. J Neurosci Res 1997; 48:238-248.
24. Cowburn RF, Fowler CJ, Garlind A, Alafuzoff I, Nilsson L, Winblad B and Bergstrom L. Somatostatin receptors and the modulation of adenylyl cyclase activity in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1991; 54:748-749.
25. Cowburn RF, O'Neill C, Bonkale WL, Ohm TG and Fastbom J. Receptor-G-protein signalling in Alzheimer's disease. Biochem Soc Symp 2001; 67:163-175.